related documents
- A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (MOBILITY-002 Trial, NCT02428270). Conferences
- Chemotherapy choice in advanced pancreatic cancer: What patient and disease factors influence prescription patterns? Conferences
- Classification of a VUS in MLH1 using a combination of family segregation studies and protein biochemistry. Conferences
- Comparative effectiveness and safety of the implementation of universal public funding of FOLFIRINOX (FFX) and gemcitabine (G) + nab-paclitaxel (GnP) in advanced pancreatic cancer (APC): A population-based study. Conferences
- Effect of PET-CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases: The long-term results of a randomized control trial. Conferences
- Major arterial resection for stage 3 adenocarcinoma of the pancreas. Conferences
- Reasons for delay in time to initiation of adjuvant chemotherapy (AC) for colon cancer (CC). Conferences
- Systematic review and meta-analysis of the effect of pre-operative PET/PET-CT in the management of patients with potentially resectable colorectal cancer liver metastasis. Conferences
- Thrombotic events in patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab. Conferences